News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Colibri Heart Valve, LLC Valve to Present Six Month Follow-up Results From First Clinical Use at Upcoming EuroPCR Meeting


5/16/2013 9:06:56 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BROOMFIELD, CO, May 16, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that Dr. Pedro Ureña will present six month follow-up results from the first-in-human implantation of the Company's proprietary transcatheter aortic heart valve. The Colibri transcatheter aortic valve implantation (TAVI) system (US Patent 8,361,144) is the world's first and only low profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system. In addition to Dr. Ureña's presentation, the Colibri TAVI system will be highlighted during a panel focused on emerging technologies. These presentations are taking place at EuroPCR 2013, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions taking place May 21-24 in Paris, France.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES